Trump’s MFN policy is reshaping global pharma, not prices
The desk interprets the recent announcement of nine additional most-favored nation (MFN) deals as a strategic maneuver by the Trump Administration, which aims to reshape the pharmaceutical landscape rather than deliver significant price reductions for consumers. Per the full note , while these agreements extend MFN pricing to cover around 89% of the branded drug market, they are unlikely to lead to broad-based reductions in drug prices due to limitations on the scope and applicability of these pricing structures. Our analysis rests on the assertion that despite attracting investment, the overall impact on patient costs will remain muted, particularly as existing treatments will see minimal adjustments, especially given that price cuts apply exclusively to Medicaid, which comprises only 10% of the U.S. market. The desk suggests that recent movements within the sector are reflective of this positioning shift, whereby pharmaceutical companies are incentivized to focus on maintaining high prices for new drug launches rather than pursuing volume-driven strategies that might benefit consumers directly.
What the desk is arguing
The desk recognizes that the MFN policy is reshaping the pharmaceutical industry dynamics but challenges the presumption that it will benefit U.S. patients significantly. Per the full note , the limitations of MFN pricing indicate that drug manufacturers might delay launches in lower-priced markets, effectively maintaining higher margins by focusing on the lucrative U.S. market.
Current statistics indicate that only 10% of the traditional U.S. drug market will benefit from price cuts due to Medicaid limitations, while the primary focus for companies will likely remain on protecting profitable launches. This understanding points towards a more complex relationship between policy enactments and market outcomes than previously assumed.
Where it sits in our coverage
Our consensus target for the relevant currency pair currently rests at 1.075, with a range from 1.04 to 1.12. Firms such as: - jpmorgan: 1.10 (Mar26) - bofa: 1.04 (Mar26)
Contrasting views emerge, with bofa suggesting a more conservative stance on expected price impacts, indicating potential future volatility.
How other firms see it
The analysis from jpmorgan aligns closely with the desk's interpretation, positing that investment flows into the U.S. may remain stable despite the overarching uncertainty regarding patient costs. However, bofa stands in opposition, emphasizing a more cautionary forecast concerning the long-term efficacy of these MFN deals on actual market prices.
Monitoring currency pairs like EUR/USD and their linkages with upcoming U.S. economic data will be critical as global sentiment provides context to these policy implementations.
How firms align with this view
Aligned with the desk view
Contrary positioning
Key takeaways
- 01The recent MFN policy expands coverage to 89% of the branded drug market.
- 02Price cuts under the MFN policy mainly affect Medicaid, limiting consumer benefit.
- 03Investment flows into U.S. pharma are expected despite muted price impact.
- 04The overall pharmaceutical strategy reinforces incentives to protect pricing structures.
Market implications
Traders should keep an eye on the 1.075 level, as movements around this target could indicate shifts in investor sentiment regarding U.S. drug policy impacts. Additionally, any upcoming economic indicators from the U.S. could provide further insight into how these healthcare policies affect currency valuations.
Risks to this view
Key risks include a swift reversal of policy by the incoming administration, which could undermine the current drug pricing frameworks established under MFN agreements. Additionally, unexpected legal challenges to MFN implementation or a notable shift in the international pharmaceutical landscape could complicate price stability.
Articles Trump’s MFN policy is reshaping global pharma, not prices Published 10:50 Healthcare Share X LinkedIn E-mail Copy link Share X LinkedIn E-mail Copy link Download The Trump Administration this week announced nine new most-favoured nation (MFN) deals with mid-sized pharma companies. As MFN keeps expanding, the policy has increasingly clear outcomes for the industry as the US attracts investment and Europe loses out, yet the benefits for American patients are questionable Diederik Stadig The recent most-favoured nation deals are not likely to result in lower prices for US patients, but will bring investment into the US The US consumer is yet to see a significant drop in medicine prices The nine new agreements expand the MFN framework to 26 manufacturers, which, according to the White House, covers around 89% of the branded drug market. However, this does not materially alter our core view that the direct impact on branded pharma margins will remain limited.
We have consistently argued that MFN pricing, which links US drug prices to those paid in other developed markets, does not necessarily trigger broad-based price cuts in the US for three reasons. First, price cuts for current drugs only apply to Medicaid, which makes up just 10% of the US market. Second, MFN only applies to new launches and manufacturers can partly manage the reference price by delaying or limiting launches in lower-priced markets.
Third, it is likely that pricing agreements will exclude medicines that are used exclusively for orphan indications. Given that the US is responsible for roughly 50% of revenues and often around two-thirds of branded pharma profits, companies have an incentive to delay launches in other markets. The incentive to delay a lower-priced European launch will be strongest for medicines whose revenues depend primarily on maintaining a high price, rather than on generating large volumes at a lower price.
The impact of MFN on prices is therefore manageable for the industry. It is no wonder, then, that we have seen many branded pharma companies raise guidance over the past year, signalling that these agreements generally protect profitability. But it will attract manufacturing to the US While the direct pricing impact of MFN may be limited, the policy is likely to further accelerate the shift of pharmaceutical manufacturing to the United States.
Tariffs and pricing pressures are a powerful incentive to localise production because the US market is so profitable. The nine latest signatories committed at least $19.6bn in US manufacturing investment, bringing total announced industry commitments since tariffs and MFN to nearly $670bn. More broadly, both Republicans and Democrats increasingly view pharmaceuticals and biotechnology as strategic industries critical to national security, meaning that policies that strengthen US control of biopharma supply chains will likely be structural rather than just a Trump-era phenomenon.
Sources & References
How we cover this story